Acinetobacter baumannii complex - Revision history

Aidan at 17:29, 22 May 2025

2025-05-22T17:29:13Z

← Older revision		Revision as of 17:29, 22 May 2025
Line 16:		Line 16:
	* Choice of antibiotic depends on susceptibility testing		* Choice of antibiotic depends on susceptibility testing
	* Possible options include:		* Possible options include:
	** [[Cefepime]], ~~[[ceftriaxone]],~~ ~~and~~ ~~[[cefotaxime]]~~		** [[Cefepime]] 2 g IV every 8 hours (infused over 3 to 4 hours)
			** [[Ceftazidime]] 2 g IV every 8 hours (infused over 3 to 4 hours)
			** [[Piperacillin-tazobactam]] 4.5 g every 8 hours (infused over 4 hours)
			** [[Ampicillin-sulbactam]] 3 g IV every 3 to 4 hours (mild, for mild) or 9 g IV every 8 hours (infused over 4 hours, for severe)
			** [[Meropenem]] 2 g IV every 8 hours (infused over 3 hours), though can do 1 g for cystitis
			** [[Imipenem]] 500 mg IV every 6 hours
			** [[Ciprofloxacin]] 400 mg IV every 8 hours or 750 mg p.o. every 12 hours
			** [[Levofloxacin]] 750 mg p.o./IV daily
			** [[Minocycline]] 200 mg p.o./IV every 12 hours or [[doxycycline]] 100 mg p.o./IV every 12 hours
	** [[Cefiderocol]]		** [[Cefiderocol]]
	** [[Carbapenems]]
	** [[Tigecycline]]		** [[Tigecycline]]
	** [[Colistin]] and [[polymyxin B]] (though [[Acinetobacter junii]] has inherent resistance)		** [[Colistin]] and [[polymyxin B]] (though [[Acinetobacter junii]] has inherent resistance)

Aidan at 02:33, 14 November 2024

2024-11-14T02:33:41Z

Aidan at 14:06, 5 May 2023

2023-05-05T14:06:19Z

← Older revision		Revision as of 14:06, 5 May 2023
Line 5:		Line 5:
	*Contains ''Acinetobacter baumannii'', ''[[Acinetobacter nosocomialis]]'', and ''[[Acinetobacter pittii]]''		*Contains ''Acinetobacter baumannii'', ''[[Acinetobacter nosocomialis]]'', and ''[[Acinetobacter pittii]]''
	*Non-motile, non-fermenting [[Stain::Gram-negative]] [[Shape::bacillus]]		*Non-motile, non-fermenting [[Stain::Gram-negative]] [[Shape::bacillus]]

			=== Antimicrobial Resistance ===

			* A number of mechanisms
			* Carbapenem resistance is usually mediated by acquisition of OXA-type class D [[Carbapenemases\|carbapenemase]]
			** Less common mechanisms include acquisition of class B (VIM, IMP, and NDM) [[carbapenemases]], loss of outer membrane CarO protein, and modification of AdeABC efflux pump

	== Management ==		== Management ==

Aidan: /* Management */

2021-11-24T20:30:19Z

Management

@@ Line 17: / Line 17: @@
 * [[Aminoglycosides]] may not penetrate well into lungs and brain, so are usually avoided
 * [[Bacteriophages]] are promising
 {{DISPLAYTITLE:''Acinetobacter baumannii'' complex}}
 [[Category:Gram-negative bacilli]]

Aidan: Text replacement - "[[Cellular shape::" to "[[Shape::"

2020-10-08T14:22:14Z

Text replacement - "[[Cellular shape::" to "[[Shape::"

← Older revision		Revision as of 14:22, 8 October 2020
Line 4:		Line 4:

	*Contains ''Acinetobacter baumannii'', ''[[Acinetobacter nosocomialis]]'', and ''[[Acinetobacter pittii]]''		*Contains ''Acinetobacter baumannii'', ''[[Acinetobacter nosocomialis]]'', and ''[[Acinetobacter pittii]]''
	*Non-motile, non-fermenting [[Stain::Gram-negative]] [[~~Cellular shape~~::bacillus]]		*Non-motile, non-fermenting [[Stain::Gram-negative]] [[Shape::bacillus]]

	== Management ==		== Management ==

Aidan at 22:48, 28 August 2020

2020-08-28T22:48:34Z

← Older revision		Revision as of 22:48, 28 August 2020
Line 1:		Line 1:
			== Background ==
⚫	* Contains ''Acinetobacter baumannii'', ''Acinetobacter nosocomialis'', and ''[[Acinetobacter pittii]]''
⚫	* Non-motile non-fermenting [[Stain::Gram-negative]] [[~~Has cell~~ shape::bacillus]]

			=== Microbiology ===

		⚫	*Contains ''Acinetobacter baumannii'', ''[[Acinetobacter nosocomialis]]'', and ''[[Acinetobacter pittii]]''
		⚫	*Non-motile, non-fermenting [[Stain::Gram-negative]] [[Cellular shape::bacillus]]

			== Management ==

			* Choice of antibiotic depends on susceptibility testing
			* Possible options include:
			** [[Cefepime]], [[ceftriaxone]], and [[cefotaxime]]
			** [[Cefiderocol]]
			** [[Carbapenems]]
			** [[Tigecycline]]
			** [[Colistin]] and [[polymyxin B]] (though [[Acinetobacter junii]] has inherent resistance)
			* [[Aminoglycosides]] may not penetrate well into lungs and brain, so are usually avoided
			* [[Bacteriophages]] are promising
	{{DISPLAYTITLE:''Acinetobacter baumannii'' complex}}		{{DISPLAYTITLE:''Acinetobacter baumannii'' complex}}
	[[Category:Gram-negative bacilli]]		[[Category:Gram-negative bacilli]]

Aidan: Text replacement - "[[Has Gram stain::" to "[[Stain::"

2020-07-05T20:47:42Z

Text replacement - "[[Has Gram stain::" to "[[Stain::"

← Older revision		Revision as of 20:47, 5 July 2020
Line 1:		Line 1:
	* Contains ''Acinetobacter baumannii'', ''Acinetobacter nosocomialis'', and ''[[Acinetobacter pittii]]''		* Contains ''Acinetobacter baumannii'', ''Acinetobacter nosocomialis'', and ''[[Acinetobacter pittii]]''
	* Non-motile non-fermenting [[~~Has Gram stain~~::Gram-negative]] [[Has cell shape::bacillus]]		* Non-motile non-fermenting [[Stain::Gram-negative]] [[Has cell shape::bacillus]]

	{{DISPLAYTITLE:''Acinetobacter baumannii'' complex}}		{{DISPLAYTITLE:''Acinetobacter baumannii'' complex}}

Aidan at 15:07, 24 October 2019

2019-10-24T15:07:50Z

← Older revision		Revision as of 15:07, 24 October 2019
Line 1:		Line 1:
	* Contains ''Acinetobacter baumannii'', ''Acinetobacter nosocomialis'', and ''[[Acinetobacter pittii]]''		* Contains ''Acinetobacter baumannii'', ''Acinetobacter nosocomialis'', and ''[[Acinetobacter pittii]]''
			* Non-motile non-fermenting [[Has Gram stain::Gram-negative]] [[Has cell shape::bacillus]]

	{{DISPLAYTITLE:''Acinetobacter baumannii'' complex}}		{{DISPLAYTITLE:''Acinetobacter baumannii'' complex}}

Aidan: Created page with "* Contains ''Acinetobacter baumannii'', ''Acinetobacter nosocomialis'', and ''Acinetobacter pittii'' {{DISPLAYTITLE:''Acinetobacter baumannii'' complex}} Category:Gram-..."

2019-08-31T11:39:23Z

Created page with "* Contains ''Acinetobacter baumannii'', ''Acinetobacter nosocomialis'', and ''Acinetobacter pittii'' {{DISPLAYTITLE:''Acinetobacter baumannii'' complex}} Category:Gram-..."

New page

* Contains ''Acinetobacter baumannii'', ''Acinetobacter nosocomialis'', and ''[[Acinetobacter pittii]]''

{{DISPLAYTITLE:''Acinetobacter baumannii'' complex}}
[[Category:Gram-negative bacilli]]

← Older revision		Revision as of 02:33, 14 November 2024
Line 27:		Line 27:

	* Infection must be distinguished from colonization of the airway or wound		* Infection must be distinguished from colonization of the airway or wound
	* Resistance may be mediated by a number of [[β-lactamases]], including OXA-24/40-like carbapenemases, ~~OCA~~-23-like carbapenemases, and metallo-β-lactamases, and often has [[sulbactam]] resistance		* Resistance may be mediated by a number of [[β-lactamases]], including OXA-24/40-like carbapenemases, OXA-23-like carbapenemases, and metallo-β-lactamases, and often has [[sulbactam]] resistance
	* Often have concurrent aminoglycoside-modifying enzymes or 16S rRNA methyltransferases, which confer resistance to [[aminoglycosides]] including [[plazomicin]]		* Often have concurrent aminoglycoside-modifying enzymes or 16S rRNA methyltransferases, which confer resistance to [[aminoglycosides]] including [[plazomicin]]
			* Refer to ESCMID guidelines[[CiteRef::paul2022eu]]
	* Single-agent treatment may be sufficient for mild infections		* Single-agent treatment may be sufficient for mild infections
	** High-dose [[ampicillin-sulbactam]] is preferred, at a dose of either 9 g IV q8h infused over 4 hours, or 27 g IV q24h continuous infusion		** High-dose [[ampicillin-sulbactam]] is preferred, at a dose of either 9 g IV q8h infused over 4 hours, or 27 g IV q24h continuous infusion
			** If susceptible, [[polymixin B]] or high-dose [[tigecycline]]
	* Combination treatment with at least two agents that have ''in vitro'' activity for most other infections		* Combination treatment with at least two agents that have ''in vitro'' activity for most other infections
	** Options include [[~~ampicillin-sulbactam~~]] ~~(preferred)~~, [[~~minocycline~~]], [[~~tigecycline~~]], [[polymyxin B~~]], and [[cefidercocol~~]]		** Options include [[minocycline]], [[tigecycline]], [[aminoglycosides]], or [[polymyxin B]]
	** [[Ampicillin-sulbactam]] may remain effective in non-susceptible isolates when used at high doses		** [[Ampicillin-sulbactam]] may remain effective in non-susceptible isolates when used at high doses
	** [[Fosfomycin]] and [[rifampin]] are not recommended		** [[Fosfomycin]] and [[rifampin]] are not recommended
	** After clinical improvement, step down to single-agent therapy		** After clinical improvement, step down to single-agent therapy
			* [[Cefiderocol]] should generally be avoided
	{{DISPLAYTITLE:''Acinetobacter baumannii'' complex}}		{{DISPLAYTITLE:''Acinetobacter baumannii'' complex}}
	[[Category:Gram-negative bacilli]]		[[Category:Gram-negative bacilli]]